Gut,

a leading international journal from BMJ and BSG, publishes cutting-edge gastroenterology and hepatology research and reviews

Impact Factor: 24.5
Citescore: 47.4
All metrics >>

Visual Abstracts

Gut Commentary Series on Digestive Health and Climate Change

Most Read Articles

Podcasts

Featured Video

Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes

Conclusion: In patients with chronic liver disease and type 2 diabetes who adhered to therapy over time, GLP1 agonists may result in lower risk of MALO. This suggests that GLP1 agonists are promising agents to reduce risk of chronic liver disease progression in patients with concurrent type 2 diabetes, although this needs to be corroborated in randomised trials.

Find out more

Related Journals